BAYHILL THERAPEUTICS BEGINS MULTIPLE SCLEROSIS TRIAL

Bayhill Therapeutics has begun dosing patients with BHT-3009, the company's experimental drug candidate, in a Phase II trial for multiple sclerosis. The study is a multi-center, double-blind, placebo-controlled evaluation with an MRI endpoint.

In the trial, researchers observed a good safety profile, and, in a small number of patients, evidence of a long-lasting antigen-specific immuno-suppression effect. The company will move to advance its second antigen-specific drug candidate, BHT-3021 for Type 1 diabetes, into Phase I/II human clinical trials.